Serial Circulating Tumor DNA Detection Using a Personalized, Tumor-Informed Assay in Esophageal Adenocarcinoma Patients Following Resection

Emma Ococks,Alexey Aleshin,Rebecca C Fitzgerald,Shruti Sharma,Alvin Wei Tian Ng,Elizabeth Smyth

doi:10.1053/j.gastro.2021.07.011

Emma Ococks, Alexey Aleshin + Show 4 more

Open Access

https://doi.org/10.1053/j.gastro.2021.07.011

Copy DOI

Abstract

Adenocarcinoma of the esophagus is rapidly increasing in incidence.1 Esophageal adenocarcinoma (EAC) is frequently advanced at presentation, and even when treated with multimodality therapy, is cured in less than 50% of operated-on patients.2,3

Highlights

Adenocarcinoma of the esophagus is rapidly increasing in incidence.[1]
Blood samples were collected from 20 patients with Esophageal adenocarcinoma (EAC) who underwent surgery or endoscopic mucosal resection (EMR)
Patients with deeper penetration of the gastroesophageal mucosa were more likely to have Circulating tumor DNA (ctDNA) identified preoperatively (9 of 12 [75%] cT3 vs 2 of 5 [40%] T2); groups were similar with respect to cN, yN, and lymphovascular invasion (Supplementary Figure 1A)

Summary

Introduction

Adenocarcinoma of the esophagus is rapidly increasing in incidence.[1]. Esophageal adenocarcinoma (EAC) is frequently advanced at presentation, and even when treated with multimodality therapy, is cured in less than 50% of operated-on patients.[2,3] Circulating tumor DNA (ctDNA) has shown promise as a prognostic tool in multiple cancers and is a predictive biomarker for treatment in non-small cell lung cancer.[4,5] We recently confirmed the prognostic value of ctDNA using a non-EAC–specific panel in a large population of resected EAC.[6]. Blood samples were collected from 20 patients with EAC who underwent surgery or endoscopic mucosal resection (EMR). All patients that recurred were ctDNA-positive at baseline (100% sensitivity, P < .0001) (Supplementary Figure 1B).

Results

Conclusion